United States · Bill · HR
H.R. 5882 (116th)
GENE Therapy Payment Act
Introduced
12 February 2020
Last action
12 February 2020 · Introduced
Status
Referred to the House Committee on Energy and Commerce.
Sponsors
Rep. Schrader, Kurt [D-OR-5], Sen. Marshall, Roger [R-KS], Rep. Crow, Jason [D-CO-6], Sen. Mullin, Markwayne [R-OK], Rep. Bera, Ami [D-CA-6], Rep. Kelly, Mike [R-PA-16], Rep. Schweikert, David [R-AZ-1]
Subjects
Healthcare
Source updated
3 January 2025
Summary
Generating Effective and Novel Evidence for Therapy Payment Act or the GENE Therapy Payment Act This bill allows state Medicaid programs to pay for certain gene therapy drugs through risk-sharing value-based payment agreements with drug manufacturers. The bill applies to covered outpatient drugs that provide potentially curative treatment for serious or life-threatening rare diseases or conditions after not more than three administrations.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
12 February 2020
Introduced
Introduced in House
Source: IntroReferral
12 February 2020
Introduced
Referred to the House Committee on Energy and Commerce.
Source: IntroReferral
12 February 2020
Introduced
Introduced in House
Source: IntroReferral
Votes
No vote records are attached yet.
Versions
- Introduced in House · 12 February 2020 · Download file
Documents
3 official files
Introduced in House (text)
This file cannot be previewed here. Use View or Download.
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Introduced in House (text)
Introduced in House · EN · 12 February 2020
Introduced in House (PDF)
Introduced in House · EN · 12 February 2020
ViewDownloadOpen at official source
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Introduced in House
summary · EN · 12 February 2020
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Sponsors
- Rep. Schrader, Kurt [D-OR-5] · D · Sponsor
- Sen. Marshall, Roger [R-KS] · R · Sponsor
- Rep. Crow, Jason [D-CO-6] · D · Sponsor
- Sen. Mullin, Markwayne [R-OK] · R · Sponsor
- Rep. Bera, Ami [D-CA-6] · D · Sponsor
- Rep. Kelly, Mike [R-PA-16] · R · Sponsor
- Rep. Schweikert, David [R-AZ-1] · R · Sponsor
- · hsif00 · Standing
Related records
- related to → Lower Costs, More Cures Act of 2019
- related to → Prescription Drug Pricing Reduction Act of 2019
- related to ← Prescription Drug Pricing Reduction Act of 2020
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/116th-congress/house-bill/5882
- Open data entity: https://api.congress.gov/v3/bill/116/hr/5882
- us · 116-hr-5882 · source updated 3 January 2025